Sample Size Effi­ci­ency of 4-Period, 2-Seq, 2-Formu­la­tion Design [RSABE / ABEL]

posted by Sereng  – USA, 2022-01-28 20:37 (681 d 09:51 ago) – Posting: # 22757
Views: 1,751

Folks, I really appreciate the guidance from this Forum. We need to conduct a 4-Period, 2-Sequence, 2-Formulation BE study per FDA "product specific guidance" (PSG). The PSG also asks us to use the RSABE approach for properly adjusting the BE acceptance criteria based on "reference variability and comparing test and referenced product within-subject variability". Can we safely assume that conducting such a replicate study would (at least) reduce our sample size by 50% over a 2-Period, 2-Sequence, 2-Formulation BE study? If correct, and assuming no more dropouts (from the longer study), would there be any additional sample size efficiency arising from the use of the RSABE? Any help would be much appreciated! Many thanks!

Complete thread:

UA Flag
 Admin contact
22,823 posts in 4,786 threads, 1,633 registered users;
24 visitors (0 registered, 24 guests [including 6 identified bots]).
Forum time: 06:29 CET (Europe/Vienna)

In these matters the only certainty is
that nothing is certain.    Pliny the Elder

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz